Haemonetics (HAE) Research & Development (2009 - 2026)

Haemonetics has reported Research & Development for 18 years, with the latest figure at $14.4 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 21.08% year-over-year to $14.4 million; the trailing twelve-month figure through Mar 2026 stood at $59.8 million (down 4.71% YoY), and the FY2026 full-year result was $59.8 million, down 4.71% from the prior year.
• Research & Development for Q1 2026 stood at $14.4 million, up from $14.2 million in the prior quarter.
• The five-year high for Research & Development was $18.3 million in Q1 2025, with the low at $10.0 million in Q1 2022.
• Average Research & Development over 5 years is $13.9 million, with a median of $14.2 million recorded in 2024.
• Year-over-year, Research & Development jumped 33.81% in 2022 and retreated 21.08% in 2026.
• Tracing HAE's Research & Development over 5 years: stood at $12.7 million in 2022, then rose by 4.54% to $13.3 million in 2023, then gained by 19.33% to $15.8 million in 2024, then declined by 10.37% to $14.2 million in 2025, then climbed by 1.83% to $14.4 million in 2026.
• The last three Research & Development figures came in at $14.4 million (Q1 2026), $14.2 million (Q4 2025), and $14.9 million (Q3 2025), per Business Quant data.

Peer Comparison